Our people

Having already headed up successful drug development companies, Vernalis plc Chief Executive Officer Ian Garland and Chief Financial Officer David Mackney are the perfect team to help Vernalis realise its potential.  They form part of a talented, highly qualified and knowledgeable senior management team.  

Within Vernalis Therapeutics, Inc. Sandford Sommer, Donna Radzik and Pascal Borderies provide a wealth of knowledge and experience in developing, manufacturing and commercializing branded prescription products in the US market.

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch